Correlation Between Sutro Biopharma and Foghorn Therapeutics

Can any of the company-specific risk be diversified away by investing in both Sutro Biopharma and Foghorn Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sutro Biopharma and Foghorn Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sutro Biopharma and Foghorn Therapeutics, you can compare the effects of market volatilities on Sutro Biopharma and Foghorn Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sutro Biopharma with a short position of Foghorn Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sutro Biopharma and Foghorn Therapeutics.

Diversification Opportunities for Sutro Biopharma and Foghorn Therapeutics

0.25

Correlation Coefficient

Sutro Biopharma  Foghorn Therapeutics

Modest diversification

The 3 months correlation between Sutro and Foghorn is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Sutro Biopharma and Foghorn Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Foghorn Therapeutics and Sutro Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sutro Biopharma are associated (or correlated) with Foghorn Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Foghorn Therapeutics has no effect on the direction of Sutro Biopharma i.e., Sutro Biopharma and Foghorn Therapeutics go up and down completely randomly.

Pair Corralation between Sutro Biopharma and Foghorn Therapeutics

Given the investment horizon of 90 days Sutro Biopharma is expected to under-perform the Foghorn Therapeutics. In addition to that, Sutro Biopharma is 1.35 times more volatile than Foghorn Therapeutics. It trades about -0.14 of its total potential returns per unit of risk. Foghorn Therapeutics is currently generating about -0.02 per unit of volatility. If you would invest  498.00  in Foghorn Therapeutics on December 19, 2024 and sell it today you would lose (54.00) from holding Foghorn Therapeutics or give up 10.84% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Sutro Biopharma  vs.  Foghorn Therapeutics

Sutro Biopharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Sutro Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Foghorn Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Foghorn Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Foghorn Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Sutro Biopharma and Foghorn Therapeutics

The main advantage of trading using opposite Sutro Biopharma and Foghorn Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sutro Biopharma position performs unexpectedly, Foghorn Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Foghorn Therapeutics will offset losses from the drop in Foghorn Therapeutics' long position.

The idea behind Sutro Biopharma and Foghorn Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.